

**BOOK NOW TO
SAVE \$600**

November 27-29, 2018 | Cambridge, MA



2nd Annual **AFDD** Anti-Fibrotic Drug Development

Translating Fibrotic Mechanisms Into Clinically Effective Therapeutics

A unique opportunity for drug developers focused on organ-specific fibrotic indications to participate in cross-disciplinary discussions

Hear from 24 expert speakers including:



Richard Marshall
Vice President,
Head of Fibrosis
GSK



Matthew Breyer
Distinguished
Scientist,
Cardiovascular &
Metabolism
**Janssen
Pharmaceuticals**



Sean Muthian
Executive Director
External Science
Innovations
Allergan



David Lagares
Principal
Investigator
**Massachusetts
General Hospital**



Peter Bunyard
Head of
Immunology
Biology
RedX Pharma

“All the speakers were superb, and every session provided novel and important insight regarding IPF. The effort the speakers put into their presentations was evident. Great job!”

Cedars-Sinai Medical Center

**Spotlight
Partner**

**InfiCure
Bio**

Tel: +1 617 455 4188 **Email:** info@hansonwade.com
www.afdd-summit.com



Welcome to the 2nd AFDD Summit

Translating Fibrotic Mechanisms into Clinically Effective Therapeutics

AFDD (Anti-Fibrotic Drug Development) is the industry definitive fibrosis forum for drug developers focused on organ specific indications to gain cross-disciplinary insights into the next generation of candidates.

Join fibrosis leaders as they **address challenges in anti-fibrotic drug development** through a tighter lens. Critically review demonstrating **clinically meaningful anti-fibrotic activity**, innovations in **preclinical modalities recapitulating fibrosis**, and **mechanisms of action of emerging candidates**.

You'll hear from 24 stakeholders including **GSK**, **Janssen** and **Celgene** as this forum equips you with the connections and actionable insights you need to advance your anti-fibrotic pipeline.

What attendees of other Hanson Wade Fibrosis Summits had to say:

Excellent opportunity to catch up with the field, **hear other industry speakers present their work**

Genentech

Valuable to talk with other companies about **approaches to challenging issues**

Merck

Very informative and well-organized conference

Celgene



Gain Leading Insights into Anti-Fibrotic Advancements

1.

Harnessing Genetics to Better Analyze Clinical Trials

Discuss how to apply functional genomic networks to inform stand alone and combination decisions to fibrotic disease; as well better classifying patients into molecular subsets for population stratification

2.

Address the Latest Advancements in Challenges with Targeted & Pleiotopic Anti-Fibrotics

Hear lessons learnt from discovery programs to date and collectively review targets of pharmacological relevance to inflammation and fibrosis

3.

Determine Advancements in Preclinical Predictability to Close Translational Gap with the Clinic

Understand advancements in biofabrication technologies of *in vitro* and recapitulation of human disease *in vivo* to improve clinical relevancy of engineered tissues

4.

Debate the Molecular Biology of Fibrosis to Better Identify Targeting Disease Pathogenesis

Critically review fibrosis as a cause or a consequence of disease and assess regenerative medicine components contributing to disease pathology

5.

Outline & Benchmark Progress Within Orphan & Chronic Fibrotic Conditions

Evaluate therapeutic advancements in cardiac fibrosis and scleroderma to better understand achieving meaningful clinical benefit with anti-fibrotics

If 150 people leave here, go out talk to their companies, their colleagues, their peers, talk about what they learnt here and make corrections: the amplification effect begins to move the field

Intercept Pharmaceuticals

24 Expert Speakers



Alexey Lugovsky
Chief Development
Officer
Morphic Therapeutics



Andy Blanchard
Director External
Discovery
GSK



Charles Theuer
Chief Executive Officer
**Tracon
Pharmaceuticals**



David Lagares
Principal Investigator
**Massachusetts
General Hospital**



Dennis Andress
Senior Medical
Director, Renal Clinical
Development
AbbVie



Gerald Horan
Director Translational
Science
Celgene



**Guillermo Torre-
Amione**
Chief Medical Officer
Cardiol Therapeutics



Harold Shlevin
Chief Executive Officer
**Galectin
Therapeutics**



Jeffrey Browning
Research Professor
Boston University



Mark Tepper
Chief Executive Officer
**Corbus
Pharmaceuticals**



Martin Phillips
Chief Executive Officer
Opsidio



Masha Poyurovsky
Vice President, Head
of Molecular Signalling
**Kadmon
Pharmaceuticals**



Matthew Breyer
Distinguished Scientist
Cardiovascular &
Metabolism
**Janssen
Pharmaceuticals**



Peter Blume-Jensen
Chief Executive Officer
Acrivon Therapeutics



Peter Bunyard
Head of Immunology
Biology
RedX Pharma



Peter Caravan
Director of the
Institute for Innovation
in Imaging
**Massachusetts
General Hospital**



Peter Traber
Partner
Alacrita Consulting



Richard Marshall
Vice President
Head of Fibrosis
GSK



Ruogang Zhao
Assistant Professor
of Biomedical
Engineering
University of Buffalo



Sean Muthian
Executive Director
External Science
Innovations
Allergan



Sofia Mayans
Chief Executive Officer
Inficure Bio



Stefan Wawersik
Associate Director
Discovery Biology
Scholar Rock



Viktor Martyanov
Research Scientist
**Geisel School of
Medicine**



Wolfgang Jarolimek
Head of Drug Discovery
Pharmaxis

Conference Day One | Wednesday, November 28, 2018

 Richard Marshall Vice President Head of Fibrosis GSK	8.20 Chair's Opening Remarks
Evaluating the Challenges & Future of Anti-Fibrotic Therapies	
 Richard Marshall Vice President Head of Fibrosis GSK	8.30 Mapping the Future of Anti-Fibrotics: Why We've Failed & What Needs to be Done for Success • Reviewing challenges in demonstrating anti-fibrotic activity to date • Assessing function as reflective of changes in fibrosis • Outlining considerations for successful anti-fibrotic clinical trials
 Sean Muthian Executive Director External Science Innovations Allergan	9.00 Measuring Anti-Fibrotic Activity • Evaluate translational potential and clinical application of biomarkers for fibrotic disease • Quantifying fibrotic progression with better discriminatory power than biopsy • Promising surrogate endpoints for current fibrosis clinical trials
	9.30 Speed Networking This session is the ideal opportunity to get face-to-face time with many of the brightest minds working in the anti-fibrotic drug development and establish meaningful business relationships for the rest of the forum.
10.00 Morning Break	
Innovations in Preclinical Modalities to Better Predict Anti-Fibrotic Activity	
 Ruogang Zhao Assistant Professor of Biomedical Engineering University of Buffalo	11.00 Improving the Clinical Relevancy of Engineered Tissues for Disease Modelling & Drug Screening in Fibrosis • Demonstrating technological innovation with improved recapitulation of human fibrosis <i>in vitro</i> • Utilizing advanced biofabrication technologies such as Organ-on-chip devices to improve the clinical relevancy of engineered tissues • Discussing results of Pirfenidone and Nintedanib as a proof of principle
 Sofia Mayans Chief Executive Officer Inficure Bio	11.30 Session Reserved for Inficure Bio
12.00 Lunch & Networking	
Utilizing Genetics for a Precision Medicine Approach to Fibrosis	
 Viktor Martyanov Research Scientist Geisel School of Medicine	1.00 Leveraging Pathways, Subsets & Networks to Better Analyze Clinical Trials: Lessons from Systemic Sclerosis • Identifying molecular response and relevant pathways modulated by treatment • Classifying patients into molecular subsets to characterize disease heterogeneity • Applying functional genomic networks to inform potential combination therapies

Re-Direction Potential of Existing Therapies to Treat Fibrotic Disease



Gerald Horan
Director Translational
Science
Celgene

1.30 Outlining Re-Direction Rationale of Existing Anti-Fibrotics to Treat Further Fibrosis Disorders

- Evaluating the preclinical efficacy of JNK inhibitors in preclinical fibrosis models and Phase 1/2 trial in IPF
- Understanding rationale of translating efficacy of JNK inhibition from IPF to SSc
- Assessing experiences with pomalidomide to inform future re-direction decisions



Charles Theuer
Chief Executive
Officer
**Tracon
Pharmaceuticals**

2.00 Targeting Endoglin: Evolving an Oncology Therapy for the Treatment of Fibrosis

- Analyzing Endoglin as an essential antigenic target expressed on tumor vasculature and fibroblasts
- Detailing the endoglin antibody carotuximab that is currently being studied in a Phase 3 trial in angiosarcoma
- Evaluating the potent anti-fibrotic effects of Carotuximab in models of cardiac, pulmonary and liver fibrosis

2.30 Afternoon Break & Networking

Cardiac Fibrosis & Scleroderma: What is Success Looking Like?



Guillermo Torre-Amione
Chief Medical Officer
**Cardiol
Therapeutics**

3.30 Anti-fibrotic Therapies for the Heart

- Addressing the challenges in targeting cardiac fibrosis
- Showcasing Cardiol Therapeutic's research



Mark Tepper
Chief Executive
Officer
**Corbus
Pharmaceuticals**


4.00 Achieving Meaningful Clinical Benefit Without Immunosuppression

- Outlining the mechanism of action of lenabasum – an oral selective CB2 agonist effective in the resolution of inflammation and fibrosis
- Reviewing the latest results from the Phase 2 study of lenabasum and ongoing openlabel extension study



Richard Marshall
Vice President
Head of Fibrosis
GSK

4.30 Chair's Closing Remarks



4.45 Poster Session

After the formal presentations have finished, the learning and networking carries on. The poster session is an informal part of the conference agenda, allowing you to connect with your peers in a relaxed atmosphere and continue to forge new and existing relationships.

“This conference was of outstanding value. First class presentations, great opportunity for networking and perfect logistics!”

AstraZeneca

“Very valuable useful information - one of the best meetings I've ever attended”

Takeda

Conference Day Two | Thursday, November 29, 2018

 Richard Marshall Vice President Head of Fibrosis GSK	8.20 Chair's Opening Remarks
Harnessing the Understanding of Molecular Pathology & Regenerative Medicine for the Identification of Druggable Targets	

 David Lagares Principal Investigator Massachusetts General Hospital	8.30 Overview of Novel Anti-Fibrotic Therapies - Discussing downstream mediators of TGFβ signalling without affecting TGFβ signalling itself - Understanding mechano biology in fibrotic disease - how to target biophysical cues and their contribution to fibrosis progression
--	--

 Alexey Lugovsky Morphic Therapeutics	
 David Lagares Massachusetts General Hospital	
 Matthew Breyer Janssen Pharmaceuticals	
 Peter Blume-Jensen Acrivon Therapeutics	9.00 Panel Discussion: Fibrosis A Cause or a Consequence? - What are the disease driving molecular alterations and processes? - Can we understand and address the gap between resolution of inflammation and fibrosis to understand the therapeutic potential of reparative inflammation? - Are there other biological pathways to consider, such as oxidative stress, as drivers of fibrosis?

9.30 Morning Break & Networking	
Clinical Trial Design to Better Demonstrate Clinically Meaningful Anti-Fibrotic Activity	

 Andy Blanchard Director External Discovery GSK	10.30 The Importance of Patient Stratification to Fibrosis Clinical Studies - Critically reviewing patient heterogeneity in fibrosis - Outlining markers of heterogeneity - Applying understanding to clinical studies
---	---

Moderated by a Selection of Leaders Including:  Dennis Andress Senior Medical Director, Renal Clinical Development AbbVie	11.00 Think Tank Roundtable Sessions Enjoy practical and highly interactive breakout roundtables where attendees can crowd-source solutions and share opinions around pre-assigned topic areas. This is a valuable chance for you to unite with your peers around hot topics and debate collectively, pre-competitively advancing drug development Tables Topics to be Determined
	11.30 Feedback Panel: Are There Commonalities Across Fibrotic Indications?

12.00 Lunch & Networking	
-------------------------------------	--

Case Studies of Anti-Fibrotic Intervention: Targetting Disease Driving Mechanisms	
--	--

 Alexey Lugovsky Chief Development Officer Morphic Therapeutics	1.00 Integrin Targets with Pharmacological Relevance in Inflammation & Fibrosis - Introducing and reviewing integrins in the context of therapeutic targets in fibrosis - Reviewing clinical precedents to date - Showcasing Morphic's integrin targeting pipeline
---	---

 Stefan Wawersik Associate Director Discovery Biology Scholar Rock	1.30 Targeting TGFβ with Biologics • Evaluating the role TGFβ and challenges of targeting TGFβ in fibrosis • Assessing antibody approaches to selectively inhibit TGFβ
 Masha Poyurovsky Vice President Head of Molecular Signalling Kadmon Pharmaceuticals	2.00 Development of 3rd Generation Rho Kinase Inhibitors Targeting Fibrotic Diseases • Outlining the central role of ROCK in biomechanical and biochemical signalling pathways • Sharing challenges and lessons learnt from initial ROCK inhibitor discovery programs • Showcasing the next generation ROCK inhibitors: safety and efficacy in fibrosis models
	2.30 Afternoon Break & Networking
Case Studies: Mechanisms of Action & New Targets in Fibrosis	
 Wolfgang Jarolimek Head of Drug Discovery Pharmaxis	3.00 Reducing Fibrosis by Inhibiting Lysyl Oxidases • Demonstrating inhibition of lysyl oxidases in the reduction of fibrosis and cancer progression • Reviewing this therapeutic approach by analyzing selective lysyl oxidase entering the clinic
 Harold Shlevin Chief Executive Officer Galectin Therapeutics	3.30 Physiological Control Systems Involving Galectins in Treatment of Diseases • Highlighting galectins as a family of highly conserved molecular effectors that mediate various biological processes • Analyzing therapeutic discovery and development for clinical intervention against fibrosis, cancer, and other disorders involving galectins • Reviewing the role of galectins in mediating physiological control processes including an understanding of structure-function relationships, mechanisms of action at the molecular level and evolving clinical data on their role in the treatment of various diseases
 Martin Phillips Chief Executive Officer Opsidio	4.00 Stem Cell Factor: A Critical Activating Mechanism in Tissue Remodeling • Debating SCF as necessary for c-kit positive immune cell recruitment and activation in fibrosis • Proving targeting the fibroblast isoform of SCF with a monoclonal antibody, OpSCF, is effective therapy in many preclinical models of remodeling and fibrosis • Showcasing OpSCF as humanized and development-ready
 Peter Bunyard Head of Immunology Biology RedX Pharma	4.30 Wnt Pathway Suppression & Fibrosis • Outlining the role of wnt protein upregulation in fibrosis and tissue remodelling, and demonstrating how wnt suppression has been shown to be an effective method of ameliorating fibrosis in several animal models • Validating porcupine inhibitors as suppressors of wnt signalling • Showcasing RedX's novel and potent porcupine inhibitor as a suppressor of fibrosis development and therapeutic potential in IPF
 Richard Marshall Vice President Head of Fibrosis GSK	5.00 Chair's Closing Remarks

Pre-Conference Workshop Day | Tuesday, November 27, 2018

Workshop A

Addressing the Complexities of Fibrosis Pathology in the Context of a Heterogeneous Pathology

8:00 – 11:00

Although the hypothesis of insult by inflammation preceding progressive fibrosis in diseases holds a lot of value, the specific aetiology and mechanisms of fibrosis manifesting in distinct organs remains uncertain. Coupled with inter individual variability, the challenges of running a successful clinical trial are significantly greater.

In this workshop, we will be:

- Overviewing what is normal and how pathology reflects dysfunction
- Critically debating and asking the question: is inflammation driving fibrosis just a hypothesis?
- Discussing the emerging role of the immune system in systemic sclerosis, specifically IL-6, toll like receptors and the use of autoantibodies as serological markers
- Speculating the likelihood of moving towards a broad spectrum anti-fibrotic and successful combination therapies effective in a wider population

Workshop Leader



Jeffrey Browning
Research Professor
Boston University

Workshop B

Non-Invasive Imaging in Liver Fibrosis

11:30 – 2:30

Non-invasive quantification of fibrosis holds value for future preclinical drug explorations and monitoring of response to therapy that would accelerate novel treatment evaluation.

Leveraging current advancements with imaging in relation to liver fibrosis is pivotal to quantifying disease non-invasively and subsequently improving vital patient recruitment and retention for clinical trials.

This workshop will explore:

- Molecular magnetic resonance imaging (MRI) to quantify liver fibrosis and fibrogenesis
- Other noninvasive methods to estimate liver fibrosis
- Multiparametric imaging- Translating preclinical observations into human trial

Workshop Leader



Peter Caravan
Director of the
Institute for
Innovation in
Imaging
**Massachusetts
General Hospital**

Lunch will
be served
during this
workshop

Workshop C

Anti-Fibrotic Drug Development in the Liver

3:00 – 6:00

With an estimated 16-30 million adults affected by NASH in the U.S. and no FDA approved treatments, the importance of addressing liver fibrosis is growing.

This workshop will give you a comprehensive overview of the translational gateway in liver fibrosis and how best to pass through it.

Attend this expert led workshop to:

- Address translational medicine in the context of liver fibrosis and NASH through a tighter lens
- Discuss translating preclinical findings into clinical programs

Workshop Leader



Peter Traber
Partner
**Alacrita
Consulting**

Partnership Opportunities

Better biomarkers to track fibrosis progression; more predictive preclinical modalities; enhanced patient recruitment and stratification are roadblocks drug developers are struggling to overcome.

AFDD is the forum designed to **showcase your solution that will enable drug developers to overcome these challenges** and accelerate drug development. Partner with AFDD to showcase your service in front of 100+ decision makers.

Be part of the industry-to-industry dialogue to generate leads, put names to faces or better understand your audience's needs.

We'll work with you to advise on and deliver a partnership to **reach your 2019 business objectives**.

To learn more about how we can support your efforts get in touch today at sponsor@hansonwade.com


Inficure
Bio

Spotlight Partner

Inficure Bio has developed a new and unique pre-clinical mouse model, the N-IF mouse, which spontaneously develops fibrosis in multiple organs. We offer expert led, tailored, high-quality drug validation services for R&D companies and CRO's. Our unique whole organism model offers extraordinary research advantages; is 100 percent reproducible, has a pathological progress similar to humans and displays a fibrosis preceded by inflammation. Inficure Bio is ready to break the status quo in anti-fibrotic drug development.

www.inficurebio.com


Previous Attendees by Seniority*



C-Level:	25%
Vice President / Head of:	22%
Senior Director/Director:	23%
Principal Scientist/Scientist:	22%
Professor:	5%
Investor:	3%

*Expected attendees for 2018 based on AFDD 2017 event attendee analysis

Previous Attendees by Company Type*



Pharma
Biotech
Academic Institute
Investors, Model Providers, Non-Invasive Diagnostics & CROs

Previous Attending Companies*



BECOME A PARTNER



Jakub Nunuk

Partnership Manager

Tel: +1 617 455 4188

Email: sponsor@hansonwade.com

Ready to register?

3 easy ways to book

-  www.afdd-summit.com/register
-  Tel: +1 617 455 4188
-  Email: register@hansonwade.com

- 1** Deepen your understanding of cross-organ fibrotic mechanisms which are driving pathology changes in humans
- 2** Evaluate innovative *in vitro* and *in vivo* models to improve preclinical predictability
- 3** Identify the potential of next generation mechanisms of action and new targets against integrin and TGF targeted compounds

Team Discounts*


- 10% discount – 3 delegates
- 15% discount – 4 delegates
- 20% discount – 5 or more delegates

*Please note that discounts are only valid when three or more delegates from one company book and pay at the same time.

Secure your place

Package Details	Register & Pay before Friday August 24, 2018	Register & Pay before Friday September 21, 2018	Register & Pay before Friday October 19, 2018	Standard Pricing
Gold: Conference & 3 Workshops	\$4296 (save \$600)	\$4396 (save \$500)	\$4496 (save \$400)	\$4596 (save \$300)
Silver: Conference & 2 Workshops	\$3697 (save \$500)	\$3797 (save \$400)	\$3897 (save \$300)	\$3997 (save \$200)
Bronze: Conference & 1 Workshop	\$3098 (save \$400)	\$3198 (save \$300)	\$3298 (save \$200)	\$3398 (save \$100)
Conference only	\$2499 (save \$300)	\$2599 (save \$200)	\$2699 (save \$100)	\$2799
Individual Workshops	\$699			

A 40% discount is available for academics upon request



VENUE

Hyatt Regency

575 Memorial Dr. Cambridge,
Massachusetts, USA, 02139-4896

For further information or assistance, please visit
www.hyatt.com

TERMS & CONDITIONS

Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time.

Changes to Conference & Agenda: Hanson Wade reserves the right to postpone or cancel an event, to change the location or alter the advertised speakers. Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities.

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Database Manager, Hanson Wade, Suite A, 6 Honduras Street, London EC1Y 0TH